These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 11371659)
1. Intravenous immunoglobulin application following immunoadsorption: benefit or risk in patients with autoimmune diseases? Schmaldienst S; Müllner M; Goldammer A; Spitzauer S; Banyai S; Hörl WH; Derfler K Rheumatology (Oxford); 2001 May; 40(5):513-21. PubMed ID: 11371659 [TBL] [Abstract][Full Text] [Related]
2. The course of anticardiolipin antibody levels under immunoadsorption therapy. Hauser AC; Hauser L; Pabinger-Fasching I; Quehenberger P; Derfler K; Hörl WH Am J Kidney Dis; 2005 Sep; 46(3):446-54. PubMed ID: 16129206 [TBL] [Abstract][Full Text] [Related]
3. New trends in specific immunoadsorption. Ullrich H; Kuehnl P Transfus Apher Sci; 2004 Jun; 30(3):223-31. PubMed ID: 15172628 [TBL] [Abstract][Full Text] [Related]
4. Low rate of infectious complications following immunoadsorption therapy without regular substitution of intravenous immunoglobulins. Tselmin S; Julius U; Bornstein SR; Hohenstein B Atheroscler Suppl; 2017 Nov; 30():278-282. PubMed ID: 29096850 [TBL] [Abstract][Full Text] [Related]
5. Ig-Therasorb immunoadsorption for selective removal of human immunoglobulins in diseases associated with pathogenic antibodies of all classes and IgG subclasses, immune complexes, and fragments of immunoglobulins. Koll RA Ther Apher; 1998 May; 2(2):147-52. PubMed ID: 10225717 [TBL] [Abstract][Full Text] [Related]
8. Immunoadsorption with regenerating systems in neurological disorders --A single center experience. Hohenstein B; Passauer J; Ziemssen T; Julius U Atheroscler Suppl; 2015 May; 18():119-23. PubMed ID: 25936315 [TBL] [Abstract][Full Text] [Related]
10. Safety Aspects of Immunoadsorption in IgG Removal Using a Single-Use, Multiple-pass Protein A Immunoadsorber (LIGASORB): Clinical Investigation in Healthy Volunteers. Süfke S; Lehnert H; Uhlenbusch-Körwer I; Gebauer F Ther Apher Dial; 2017 Aug; 21(4):405-413. PubMed ID: 28508563 [TBL] [Abstract][Full Text] [Related]
11. Performance, clinical effectiveness, and safety of immunoadsorption in a wide range of indications. Fuchs K; Rummler S; Ries W; Helmschrott M; Selbach J; Ernst F; Morath C; Gauly A; Atiye S; Stauss-Grabo M; Giefer M Ther Apher Dial; 2022 Feb; 26(1):229-241. PubMed ID: 33914397 [TBL] [Abstract][Full Text] [Related]
12. Immunoadsorption in the treatment of pemphigus. Mlynek A; Meurer M Atheroscler Suppl; 2009 Dec; 10(5):107-9. PubMed ID: 20129386 [TBL] [Abstract][Full Text] [Related]
13. [Intravenous immunoglobulins. General features and the main clinical applications]. Agostini G; Antonelli A Clin Ter; 1992 Sep; 141(9 Pt 2):17-32. PubMed ID: 1468194 [TBL] [Abstract][Full Text] [Related]
14. Successful and well-tolerated bi-weekly immunoadsorption regimen in pemphigus vulgaris. Dietze J; Hohenstein B; Tselmin S; Julius U; Bornstein SR; Beissert S; Günther C Atheroscler Suppl; 2017 Nov; 30():271-277. PubMed ID: 29096849 [TBL] [Abstract][Full Text] [Related]
15. Normal polyspecific immunoglobulin G (IVIg) in the treatment of autoimmune diseases. Hurez V; Kaveri SV; Kazatchkine MD J Autoimmun; 1993 Dec; 6(6):675-81. PubMed ID: 8155249 [TBL] [Abstract][Full Text] [Related]
16. Treatment of antibody-mediated rejection including immunoadsorption during first year after renal transplantation--Clinical results and regulation of endothelial progenitor cells. Opgenoorth M; Wagner A; Passauer J; Hohenstein B; Hugo C Atheroscler Suppl; 2015 May; 18():67-73. PubMed ID: 25936307 [TBL] [Abstract][Full Text] [Related]
18. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins. Shimanovich I; Nitschke M; Rose C; Grabbe J; Zillikens D Br J Dermatol; 2008 Feb; 158(2):382-8. PubMed ID: 18070210 [TBL] [Abstract][Full Text] [Related]
19. Immunoadsorption onto protein A induces remission in severe systemic lupus erythematosus. Braun N; Erley C; Klein R; Kötter I; Saal J; Risler T Nephrol Dial Transplant; 2000 Sep; 15(9):1367-72. PubMed ID: 10978392 [TBL] [Abstract][Full Text] [Related]
20. Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial. Greinacher A; Friesecke S; Abel P; Dressel A; Stracke S; Fiene M; Ernst F; Selleng K; Weissenborn K; Schmidt BM; Schiffer M; Felix SB; Lerch MM; Kielstein JT; Mayerle J Lancet; 2011 Sep; 378(9797):1166-73. PubMed ID: 21890192 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]